Adoptive immunotransfer with viable donor mononuclear cells for recurrent chronic myelogenous leukemia after allogeneic bone marrow transplantation in two children.
Two children with Ph+ chronic myelogenous leukemia (CML) relapsed in the chronic phase after allogeneic bone marrow transplantation (BMT). They were treated with transfusions of peripheral blood mononuclear cells (PBMC) obtained from the former bone marrow donors in combination with interferon alfa-2. In one child, CML was successfully controlled as shown by disappearance of Ph+ metaphases as well as negativity for BCR-ABL fusion gene transcripts demonstrated by polymerase chain reaction (PCR) analysis. The patient has remained in complete remission without evidence of disease for 12 months after donor PBMC transfusions. The other child showed disappearance of BCR-ABL gene transcripts by PCR analysis only in peripheral blood cells, but PCR positivity persisted in bone marrow samples. These results indicate that adoptive immunotherapy may be a further alternative in children with relapse of CML after allogeneic BMT as previously described for adult patients.
Schwinger
W
W
Division of Hematology-Oncology, Children's Clinic, University of Graz, Austria.
Urban
C
C
Mache
C J
CJ
Resch
B
B
Lackner
H
H
Höfler
G
G
Beham-Schmid
C
C
Gilli
R
R
Wagner
K
K
Haas
O A
OA
D000293:Adolescent; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D012008:Recurrence; D014184:Transplantation, Homologous